A step forward in the characterization and treatment of breast cancer
Keywords:
BREAST NEOPLASMS, RISK FACTORS, WOMEN, GENES.Abstract
Introduction: breast cancer is the most frequent pathology within carcinomas occurring in females. It happens when breast cells grow uncontrolled due to failure of proliferative regulatory mechanisms. Current treatments involve high adverse effects for the health of patients and the efficacy in many cases is not as expected.
Objective: to describe the advances in the treatment of breast carcinoma which are based on high biological activity, selectivity and low toxicity.
Methods: articles related to the research were taken from SciELO, Pubmed, Springer, ScienceDirect, Mediagraphic and Redalyc databases. Theoretical methods of analysis and synthesis allowed the study of the topic in question, and 75 % of the publications of the last three years were chosen.
Development: work is currently underway on the development of new drugs against breast cancer including STAT3 transcription factor inhibitors, PARP poly-ADP-ribose polymerase (PARP) inhibitors and the use of micro-RNA biomarkers. Molecular docking techniques have allowed the design of estrogen receptor and human epidermal growth factor inhibitors with lower energy values than natural compounds.
Conclusions: the development of potential candidates aims at decreasing tumor toxicity and invasiveness as well as increasing selectivity and biological activity. The design of master keys may be an attractive option against breast cancer.
Downloads
References
1. Ramírez Valle M, García Montesino G. Cáncer de mama invasivo según subtipos moleculares en la provincia de Pinar del Río. Rev Ciencias Médicas. [Internet]. 2020 [citado 2021/05/16]; 24(5): e4362. Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/4362
2. Ramírez Valle M, García Montesino G, Lores Hechevarria C, Sánchez Azcuy Y, Márquez Hernández C. Histological and immunohistochemistry of invasive breast cancer in Pinar del Río province Cuba. Rev Ciencias Médicas. [Internet]. 2019 [citado 2021/03/01]; 23(1): 71-78. Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/3801
3. Valdés Lara G, García Espinosa A, Pedroso Morales I. La rehabilitación del cáncer de mama en Cuba. Rev Invest. Medicoquir [Internet]. 2019 [citado 2021/05/13]; 11(supl.1): [aprox. 18 pp.]. Disponible en: https://www.medigraphic.com/pdfs/invmed/cmq-2019/cmqs191v.pdf
4. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario estadístico 2018. La Habana: MINSAP[Internet]; 2019. Disponible en: https://files.sld.cu/bvscuba/files/2019/04/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2018-ed-2019-compressed.pdf
5. Peña García Y, Maceo González M, Ávila Céspedes D, Utria Velázquez L, Más López Y. Factores de riesgo para padecer cáncer de mama en la población femenina. Rev Finlay [Internet]. 2017 [citado 2021/02/25]; 7(4): 283-289. Disponible en: http://scielo.sld.cu/pdf/rf/v7n4/rf08407.pdf
6. Echevarría Lores C. El carcinoma de mama. Caracterización clínico-patológica en un hospital de la atención secundaria pinareña. Rev Ciencias Médicas [Internet]. 2016 [citado 2021/05/13]; 20(1): 75-79. Disponible en: http://www.revcmpinar.sld.cu/index.php/publicaciones/article/view/2542
7. Raya Pérez JC. Las bases moleculares del cáncer. Acta Universitaria [Internet]. 2006 [citado 2021/02/28]; 16(1): 40-49. Disponible en: https://www.redalyc.org/pdf/416/41616105.pdf
8. Hernández DE. Biología del cáncer de mama. Rev Venez Oncol [Internet]. 2016 [citado 2021/03/02]; 28(3): 188-200. Disponible en: https://www.redalyc.org/pdf/3756/375645930010.pdf
9. Sherr CJ. Principles of tumor suppression. Rev Cell [Internet]. 2004 [citado 2021/03/02]; 116(2): 235-246. Disponible en: https://www.sciencedirect.com/science/article/pii/S0092867403010754
10. Isakoff SJ. Triple Negative Breast Cancer: Role of Specific Chemotherapy Agents. Cancer J [Internet]. 2010 [citado 2021/03/2]; 16(1): 53–61. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882502/
11. Waks A, Winer E. Breast Cancer Treatment. A Review. JAMA [Internet]. 2019 [citado 2021/02/28]; 321(3): 288-300. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/2721183
12. Joshi Himanshu MF. Press. Molecular oncology of breast cancer. The Breast [Internet]. 2018 [citado 2021/02/28]; (22): 282-307. Disponible en: https://www.sciencedirect.com/science/article/pii/B9780323359559000222
13. Yuan J, Xiao C, Lu H, Yu H, Hong H, Guo C et al. Effects of various treatment approaches for treatment efficacy for late stage breast cancer and expression level of TIMP-1 and MMP-9. Cancer Biomarkers [Internet]. 2018 [citado 2021/02/25]; 23(1): 1–7. Disponible en: https://content.iospress.com/articles/cancer-biomarkers/cbm170901
14. Smith J, Buyse M, Rastogi P, Geyer C, Jacobs S, Patocskai E, et al. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. Clin Breast Cancer [Internet]. 2017 [citado 2021/02/28]; 17(1): 48-54. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1526820916302014
15. Khosravi Shahi P, Cabezón Gutiérrez L, Custodio Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol [Internet]. 2018 [citado 2021/02/28]; 14(1): 32–39. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.12748
16. Halil Yildirim I, Ahmed Azzawri A, Duran T. Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells. Dicle Tip Dergisi/Dicle Med [Internet]. 2019 [citado 2021/02/25]; 46(3): 411–417. Disponible en: https://dergipark.org.tr/en/download/article-file/808246
17. Allahverdiyev AM, Parlar E, Dinparvar S, Bagirova M, Sefik Abamor S. Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects. Artificial cells, Nanomedicine, and Biotechnology [Internet]. 2018 [citado 2021/02/28]; 46(3): S755-S762. Disponible en: https://www.tandfonline.com/doi/full/10.1080/21691401.2018.1511573
18. Qin J, Yan L, Zhang J, Zhang W. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. Journal of Experimental and Clinical Cancer Research [Internet]. 2019 [citado 2021/02/28]; 38(195): 1-16. Disponible en: https://link.springer.com/article/10.1186/s13046-019-1206-z
19. Adhami M, Akbar Haghdoost A, Malekpour Afshar R. Candidate miRNA in human breast cancer biomarkers: a systematic review. Breast Cancer [Internet]. 2018 [citado 2021/03/02]; 25: 198-205. Disponible en: https://link.springer.com/article/10.1007/s12282-017-0814-8
20. Papadimitriou M, Mountzios G, Papadimitrioua C. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum on syntetic lethality. Cancer treatment reviews [Internet]. 2018 [citado 2021/03/02]; 67: 37-44. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0305737218300549
21. Márquez Fernández ME, Camargo M. Therapeutic potential of omega fatty acids in breast cancer. Vitae [Internet]. 2019 [citado 2021/02/26]; 2(1): 23-43. Disponible en: http://www.scielo.org.co/scielo.php?pid=S0121-40042019000100023&script=sci_arttext&tlng=en
22. De Cicco P, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment and Recurrence. Nutrients [Internet]. 2019 [citado 2021/02/28]; 11(7): 1514. Disponible en: https://www.mdpi.com/2072-6643/11/7/1514
23. León Barrios Y, Céspedes Quevedo M, Vinent Céspedes A. Neutropenia inducida por citostáticos en oncología. Medisan [Internet]. 2017 [citado 2021/03/01]; 21(11): 3163-3171. Disponible en: https://www.medigraphic.com/pdfs/medisan/mds-2017/mds1711d.pdf
24. Soriano García J, Batista Albuerne N, Lima Pérez M, González González J, Gutiérrez Rojas A, Luaces Álvarez P. Evaluación del uso de ácido zoledrónico en pacientes con cáncer de mama metastásico a hueso. Rev Cubana de Medicina [Internet]. 2010 [citado 2021/03/01]; 49(1): 33-64. Disponible en: http://scielo.sld.cu/pdf/med/v49n1/med04110.pdf
25. Portelles Cruz A, Rodríguez Alberteris Y, Fernández Sarabia P, Sanz Pupo N, Oller Pousada J. Quimioterapia neoadyuvante en cáncer de mama, localmente avanzado. Rev CCM [Internet]. 2013 [citado 2021/03/01]; 17(4): 433-442. Disponible en: http://scielo.sld.cu/pdf/ccm/v17n4/ccm03413.pdf
26. Soriano García J, Lima Pérez M, Batista Albuerne N, González González J, Manuel Pangui S. Evaluación del uso del esquema de paclitaxel con carboplatino en pacientes con cáncer de mama metastásico. Revista Cubana de Medicina [Internet]. 2009 [citado 2021/03/02]; 48(2): 1-15. Disponible en: http://scielo.sld.cu/pdf/med/v48n2/med03209.pdf
27. Parvizpour S, Razmara J, Pourseif M, Omidi Y. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. BioImpacts [Internet]. 2019 [citado 2021/03/02]; 9(1): 45-56. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378095
28. Speck Planche A, Cordeiro N. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteíns. Molecular Diversity [Internet]. 2017 [citado 2021/03/04]; 21: 511-523. Disponible en: https://link.springer.com/article/10.1007/s11030-017-9731-1
29. Sinha S, Patel S, Athar M, Vora J, Chhabria MT, Jha PC, Shrivastava N. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study. Rev Int J Biol Macromol [Internet]. 2019 [citado 2021/02/25];140: 454-468. Disponible en: https://www.sciencedirect.com/science/article/pii/S0141813019343594
30. Suryani Y, Opik T, Siti R, Ida K, Epa P. In silico analysis of formononetin compound as a breast anti cancer. Rev Latinoamérica de Hipertensión [Internet]. 2018 [citado 2021/02/26]; 13(6): 579-583. Disponible en: http://digilib.uinsgd.ac.id/id/eprint/31047
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
